Keyword Analysis & Research: apydan
Keyword Research: People who searched apydan also searched
Search Results related to apydan on Search Engine
-
Apydan: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
https://www.medicinesfaq.com/brand/apydan
WEBSep 19, 2023 · Apydan is a medication used to treat epilepsy and bipolar disorder. For epilepsy it is used for both focal seizures and generalized seizures. Apydan is an antiepileptic medication that works in the brain to prevent and control seizures. It is approved for the treatment of partial seizures.
DA: 69 PA: 5 MOZ Rank: 52
-
Extended-release antiepileptic drugs: A ... - Wiley Online Library
https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12043
WEBNov 28, 2012 · A multiple-dose PK comparison of IR oxcarbazepine versus Apydan, both given twice daily, was notable for a 44% reduction in oxcarbazepine C max with Apydan; however, the C max and AUC for the monohydroxy derivative (MHD) between the two formulations were nearly identical (Steinhoff, 2009).
DA: 92 PA: 10 MOZ Rank: 42
-
Oxcarbazepine - Wikipedia
https://en.wikipedia.org/wiki/Oxcarbazepine
WEBOxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. [3] [5] For epilepsy it is used for both focal seizures and generalized seizures. [6] . It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments.
DA: 42 PA: 20 MOZ Rank: 37
-
Oxtellar XR: Package Insert - Drugs.com
https://www.drugs.com/pro/oxtellar-xr.html
WEBLast updated on Jan 2, 2024. On This Page. Indications and Usage. Dosage and Administration. Dosage Forms and Strengths. Contraindications. Warnings and Precautions. Adverse Reactions/Side Effects. Drug Interactions. Use In Specific Populations. Drug Abuse and Dependence. Description. Overdosage. Clinical …
DA: 21 PA: 90 MOZ Rank: 14
-
Modified-Release Formulations of Second-Generation …
https://link.springer.com/article/10.1007/s40263-015-0268-5
WEBSep 14, 2015 · Approved indications include treatment of seizures (Lamictal XR ®, Keppra XR ®, Oxtellar XR ®, Apydan ® extent, Qudexy XR™, Trokendi XR™), post-herpetic neuralgia (Gralise ®, Horizant ®) and restless leg syndrome (Horizant ®). The primary advantage of the new formulations is once-daily dosing to improve convenience and …
DA: 43 PA: 68 MOZ Rank: 43
-
(PDF) Oxcarbazepine extended-release formulation in epilepsy
https://www.researchgate.net/publication/233670758_Oxcarbazepine_extended-release_formulation_in_epilepsy
WEBMar 1, 2009 · PDF | Oxcarbazepine (OXC) is a 10-keto-analogue of carbamazepine, which was developed and labeled as a follow-up antiepileptic drug, that was intended... | Find, read and cite all the research you...
DA: 31 PA: 39 MOZ Rank: 89
-
PharmGKB
https://www.pharmgkb.org/chemical/PA450732/prescribingInfo
WEBIn case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs. Screening for HLA-B*1502 in population groups with low prevalence is not required. Similarly, screening is not appropriate for patients ...
DA: 62 PA: 13 MOZ Rank: 34
-
PharmGKB
https://www.pharmgkb.org/labelAnnotation/PA166184173
WEBSummary. The Swiss label for oxcarbazepine (Apydan® extent) states that patients who have an increased risk of SJS/TEN should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent.
DA: 77 PA: 37 MOZ Rank: 17
-
APYDAN - Drug - RxReasoner
https://www.rxreasoner.com/drugs/apydan
WEBAPYDAN - Drug - RxReasoner. This brand name is authorized in Estonia , Finland. Active ingredients. The drug APYDAN contains one active pharmaceutical ingredient (API): 1 Oxcarbazepine. UNII VZI5B1W380 - OXCARBAZEPINE. The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD).
DA: 98 PA: 32 MOZ Rank: 45
-
Oxcarbazepine extended-release formulation in epilepsy
https://pubmed.ncbi.nlm.nih.gov/24410646/
WEBBoth possibilities offer a profile approaching the characteristics of an extended-release (ER) formulation. ER OXC was labeled in Germany in 2008 (Apydan(®) extent, Desitin Arzneimittel GmbH, Hamburg, Germany). Under steady-state conditions, Phase I studies show bioequivalence between IR and ER OXC.
DA: 24 PA: 35 MOZ Rank: 60
